Previous studies prove that an individual with type 2 diabetes is at enhanced risk of serious health conditions such as heart attacks and stroke due to low HDL cholesterol levels and high triglycerides levels. A study funded by National Heart, Lung and Blood Institute (NHLBI) Bethesda shows fenofibrate therapy can reduce risk associated with strokes and heart attacks in patients with type 2 diabetes even though the patient is with high levels of fat (and triglycerides ), low levels of HDL cholesterol and taking statins medications.
Researchers investigated whether
Researchers have done follow up studies on 4,640 individuals. The study results show fenofibrate therapy helps an individual in lowering cardiovascular symptoms in type 2 diabetes individuals with high triglycerides and low HDL cholesterol levels even though the individual is under statins medications. Researchers say a random study is required to confirm the current findings. Study findings were published in the JAMA Cardiology.
Fenofibrate : Fenofibrate medications are being used since 1975. They are a class of amphipathic carboxylic acids and hypolipidemic agents, recommended by doctors if the patient can't take statin drugs, to reduce LDL cholesterol and triglycerides levels in the blood (a risk factor to atherosclerosis - blockage of arteries). But these medications are less effective compared with statin drugs. But they are effective in controlling other health aspects such as metabolic disorders, hypercholesterolemia (high amounts of cholesterol in the blood) and hypertriglyceridemia (high levels of triglycerides in the blood). Previous studies show fenofibrate medications can prevent microvascular events. Side effects with fenofibrate medications are a headache, nausea, back pain, arthralgia (joint pain), nasopharyngitis (cold - infection in nose and throat), myalgia (muscle pain), diarrhoea (or diarrhea) and respiratory tract infection.
There are drugs to treat symptoms of Parkinson's disease but no drugs to treat causes of the disease. Previous studies show metabolic changes at the molecular level are similar in diabetes and Parkinson's disease. This phenomenon gave interest to researchers to find out working of thiazolidinediones drugs such as MSDC-0160 (a drug developed earlier to cure type 2 diabetes) to treat causes of Parkinson's disease after studying more than 120 potential treatments.
Researchers conducted trials on animal models with a MSDC-01600 drug to cure Parkinson's disease. All clinical trial models are showing the slowdown in the progression of Parkinson's disease. The MSDC-0160 drug is successful in controlling functionality of the brain cells by restoring mitochondrial function, leading to reduced brain cell death and inflammation.
Researchers say the current drug can treat patients suffering from cognitive conditions such as Alzheimer's disease and dementia. Now researchers working on conducting human trials as early as possible. Part of the study was funded by Cure Parkinson's Trust, a London based charity. Senior author of the study is Dr. Patrik Brundin, MD, PhD and the study findings were published in the Science Translational Medicine.
Parkinson's disease : A damage to the central nervous system causing a drop in dopamine (a neurotransmitter) levels. Damage to nerves system affects muscles, speech, tremors, stiffness and loss of balance. An individual may be affected between the ages of 50 and 60.
Thiazolidinediones : Oral hypoglycemic drugs used to treat type 2 diabetes. Combination drugs of thiazolidinediones are also available, intended to lower insulin resistance in fat and muscle of the body. These drugs may reduce triglycerides and improve HDL levels. Call a doctor if thiazolidinediones drug patient experience side effects such as breathing trouble, chest pain, nausea, vomiting and swelling (in lips, face, throat or tongue).
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.